SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sai Life Sciences soars on commencing commercial operations of Unit IV Bidar facility in Karnataka

20 Jun 2025 Evaluate

Sai Life Sciences is currently trading at Rs. 756.85, up by 27.65 points or 3.79% from its previous closing of Rs. 729.20 on the BSE.

The scrip opened at Rs. 735.00 and has touched a high and low of Rs. 766.55 and Rs. 720.35 respectively. So far 20991905 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 808.20 on 26-Dec-2024 and a 52 week low of Rs. 635.30 on 09-Apr-2025.

Last one week high and low of the scrip stood at Rs. 772.60 and Rs. 716.00 respectively. The current market cap of the company is Rs. 15535.19 crore.

The promoters holding in the company stood at 35.17%, while Institutions and Non-Institutions held 25.62% and 39.21% respectively.

Sai Life Sciences has commenced commercial operation of the second phase of the production block with 91 kL of capacity at its Unit IV Bidar facility in Karnataka, India, on June 19, 2025. This is the second and final phase of the overall capacity addition of 195 kL which was under construction at Unit IV Bidar Facility as disclosed in the prospectus. 
Accordingly, the combined capacity of Unit IV Bidar Facility will be 640 kL which will be equipped to supply registered starting materials (RSM), intermediates, and active pharmaceutical ingredients (APIs) for both clinical and commercial purposes.

Sai Life Sciences is a pure play fully-integrated, innovator-focused, contract research, development and manufacturing organization.

Sai Life Sciences Share Price

1194.45 5.60 (0.47%)
11-Jun-2026 09:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1787.75
Dr. Reddys Lab 1273.55
Cipla 1381.70
Zydus Lifesciences 1100.15
Lupin 2257.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×